sulfasalazine has been researched along with Coronary Artery Disease in 2 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We treated patients with coronary artery disease with sulfasalazine, an inhibitor of NFκB, and placebo in a randomized, double-blind, crossover study design." | 9.16 | Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. ( Dohadwala, MM; Duess, MA; Frame, AA; Hamburg, NM; Holbrook, M; Keaney, JF; Kim, BH; Kluge, MA; Levit, A; Shenouda, SM; Tabit, CE; Vita, JA; Widlansky, ME, 2012) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 7.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| " We treated patients with coronary artery disease with sulfasalazine, an inhibitor of NFκB, and placebo in a randomized, double-blind, crossover study design." | 5.16 | Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. ( Dohadwala, MM; Duess, MA; Frame, AA; Hamburg, NM; Holbrook, M; Keaney, JF; Kim, BH; Kluge, MA; Levit, A; Shenouda, SM; Tabit, CE; Vita, JA; Widlansky, ME, 2012) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 3.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, LC | 1 |
| Leong, PY | 1 |
| Yeo, KJ | 1 |
| Li, TY | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Tabit, CE | 1 |
| Holbrook, M | 1 |
| Shenouda, SM | 1 |
| Dohadwala, MM | 1 |
| Widlansky, ME | 1 |
| Frame, AA | 1 |
| Kim, BH | 1 |
| Duess, MA | 1 |
| Kluge, MA | 1 |
| Levit, A | 1 |
| Keaney, JF | 1 |
| Vita, JA | 1 |
| Hamburg, NM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sulfasalazine on Endothelial Function[NCT00554203] | 60 participants (Anticipated) | Interventional | 2003-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sulfasalazine and Coronary Artery Disease
| Article | Year |
|---|---|
Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Boston; Brachial Ar | 2012 |
1 other study available for sulfasalazine and Coronary Artery Disease
| Article | Year |
|---|---|
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis | 2016 |